about
Effect of pioglitazone treatment on behavioral symptoms in autistic childrenPioglitazone for type 2 diabetes mellitusPPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China.The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users.Effects of long-term pioglitazone treatment on peripheral and central markers of aging.Current oral agents for type 2 diabetes. Many options, but which to choose when?Methylsulfonylnitrobenzoates, a new class of irreversible inhibitors of the interaction of the thyroid hormone receptor and its obligate coactivators that functionally antagonizes thyroid hormone.Oral combination therapy for type 2 diabetes.Insulin sensitisation in the treatment of Type 2 diabetes.PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43.Investigation of the antibacterial activity of pioglitazone.Preparation and characterization of pioglitazone cyclodextrin inclusion complexes.Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.The pharmacokinetics of pioglitazone in patients with impaired renal function.Clinical neuroprotective drugs for treatment and prevention of stroke.Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality.A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetesPioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.Gender-specific differences in PPARγ regulation of follicular helper T cell responses with estrogenExposure to fine airborne particulate matters induces hepatic fibrosis in murine models.Biological Rationale for the Use of PPARγ Agonists in GlioblastomaMethyl 2-((2Z,5Z)-4-oxo-3-phenyl-2-{2-[(1E)-1,2,3,4-tetra-hydro-naphthalen-1-yl-idene]hydrazin-1-yl-idene}-1,3-thia-zolidin-5-yl-idene)acetate.Review of approved pioglitazone combinations for type 2 diabetes.Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders.Understanding the molecular dynamics of type-2 diabetes drug target DPP-4 and its interaction with Sitagliptin and inhibitor Diprotin-A.Effect of thiazolidinediones on the erythropoeitic and germinal cells in the male wistar rats.Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.MK886 inhibits the pioglitazone-induced anti-invasion of MDA-MB-231 cells is associated with PPARα/γ, FGF4 and 5LOX.Insulin sensitizing pharmacology of thiazolidinediones correlates with mitochondrial gene expression rather than activation of PPAR gamma.Synthesis of tryptoline-3-carboxylic Acid derivatives a novel antidiabetic agentThe Role of PPARγ in the Transcriptional Control by Agonists and Antagonists.Inflammatory responses in the atria: should they stay or should they go?Analgesic tolerance to morphine is regulated by PPARγ.Effects of combined pioglitazone and metformin on diabetes and obesity in Wistar fatty rats.Biochemical alterations and liver toxicity analysis with pioglitazone in healthy subjects.Quercetin Improves Glucose and Lipid Metabolism of Diabetic Rats: Involvement of Akt Signaling and SIRT1.Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone.Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study.Pioglitazone abolishes autistic-like behaviors via the IL-6 pathway.Comparative in vitro-in vivo correlation analysis with pioglitazone tablets
P2860
Q21245241-7B438749-5F79-4477-92FC-D90CDC205F19Q24244321-2FE981F6-C628-4177-9FA5-118F207098AEQ33572403-F74329B0-5DEF-4D52-91CB-37080F56A6D4Q33727021-0120B2CB-CD20-4F77-8261-6E9B94B418BAQ33818388-005E924C-3787-44D2-A6E1-9B044D70A6BFQ34663240-E5DE2D80-00AC-4012-8979-4ECA81D7F65FQ34751984-6FA9031C-12B2-4AEF-BEA5-AFA27A727D8AQ34906456-910312D1-BA68-40AD-A8A7-86C2792EB91DQ35073317-9050C7C6-35B5-40A3-8460-ED4D2482529BQ35239387-C375B80C-2C48-41D9-B49A-1A150418404CQ35533449-01DCFA9A-59AF-4704-80A5-794BA036D39CQ35646232-9A98CB66-7724-4300-BF63-9B5B72CC544AQ35745608-7E08A957-FDBA-41E8-BAEB-B87B844CE8FBQ35825291-98A5D9D4-CF7A-4E45-9202-2C3F8F8C7C99Q36097037-E057480F-F674-4B6F-86E7-26A7C5DABD24Q36407383-080078A2-FE1A-43EF-A0D3-8045418794A5Q36536205-589F665F-A5F9-4787-8408-0A59391A7102Q36569766-F31E1AFF-B0F8-4135-AC90-B13F3766E48EQ37030803-F73DCF9C-847C-4613-8416-7A762A20D455Q37213928-54F460A6-18D4-4385-8131-54BB94CD4080Q37636459-8F398288-C396-41D8-8DEA-5CB129E98B96Q37721392-7F6594EB-3120-48E8-A64F-1F3B5961915BQ37884618-B84B7B77-5C71-4B39-ABCF-0B0EED2B4F20Q38066606-155D5BC5-1ADD-491D-B532-E9848C28C852Q38210234-8EA6FDB8-2410-4015-89EA-2A203FEAE2E4Q38260621-3AFE137D-C7C0-4FFA-97D5-549D91AE5736Q38455771-03E0ECBE-B88C-49C3-A996-3E3173F64AE7Q41639652-8BA5377A-17C5-4AD2-9359-E74BDFD6DE4EQ42003574-F9122E19-41B9-429C-9496-1218D46A8971Q42155492-1C563E49-6AFD-4E87-AA4C-83033C8E117FQ42185295-8B419F0F-0413-4531-B11D-DA4824138FC7Q42694091-A6EDFCAD-0B46-48BC-89F8-AC07FDEC3EFCQ43105759-9D6BBBEB-23E9-4410-A54E-CC34BBA0ED1BQ43977158-92A2F428-12ED-4A2C-91F3-8609B986FC22Q45111558-0E16FD83-4284-4068-BE50-27E249C76F4CQ48146151-730DC79F-89B8-453E-807D-18C66284BB21Q53086784-F3C959BC-0963-483D-AC56-F98FD5DAC7E4Q53645972-3A0F397F-C07A-4DDC-B762-35F6DCF5B06DQ54201255-BAACEE7D-0D0D-4D8E-B42E-CCFC046E85DAQ57932324-F5B7D723-352E-4E06-9772-9AA3D4F60A20
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Pioglitazone.
@ast
Pioglitazone.
@en
type
label
Pioglitazone.
@ast
Pioglitazone.
@en
prefLabel
Pioglitazone.
@ast
Pioglitazone.
@en
P1433
P1476
Pioglitazone.
@en
P2093
P304
333-43; discussion 344-5
P356
10.2165/00003495-200060020-00009
P577
2000-08-01T00:00:00Z
P6179
1038427503